Literature DB >> 29629647

Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray.

Duncan S Russell1,2, Lauren Jaworski1,2, William C Kisseberth1,2.   

Abstract

Although inactivating mutations of tumor suppressor genes are well described in cell lines of canine osteosarcoma (OS), expression of tumor suppressor proteins in spontaneous disease is poorly characterized. We determined the immunohistochemical expression of p53, PTEN, Rb, and p16 in a large cohort of dogs with OS. Formalin-fixed, paraffin-embedded samples of canine OS were analyzed retrospectively. Primary tumor samples from 145 dogs, collected between 2003 and 2008, were evaluated by tissue microarray. Streptavidin-biotin complex immunohistochemistry was performed using monoclonal antibodies for Rb and PTEN and polyclonal antibodies for p16 and p53. The average age of dogs was 7.6 y, and 118 of 145 (81%) were purebred. Most commonly represented purebreds were Greyhound (23%), Rottweiler (11%), and Labrador Retriever (10%). Immunohistochemical detection of p53, PTEN, Rb, and p16 was 81%, 61%, 66%, and 66%, respectively. The staining pattern for p16 was primarily cytoplasmic; the predominant pattern for PTEN, Rb, and p53 was cytoplasmic and nuclear. Exclusively cytoplasmic staining was noted in 19% of samples positive for p53 and 8% of samples positive for Rb. Kaplan-Meier curves showed that protein expression was not associated with significant differences in overall survival ( p > 0.191). We documented heterogeneity in both immunostaining and subcellular localization of tumor suppressor proteins, providing further characterization of canine OS.

Entities:  

Keywords:  CDKN2A/B; Greyhound; cyclin-dependent kinase; dogs; osteosarcoma; tumor suppressor gene

Mesh:

Substances:

Year:  2018        PMID: 29629647      PMCID: PMC6505918          DOI: 10.1177/1040638718770239

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  38 in total

1.  Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis.

Authors:  Ji-Hyun Chung; Charis Eng
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

2.  Nuclear PTEN: a tale of many tails.

Authors:  A Gil; A Andrés-Pons; R Pulido
Journal:  Cell Death Differ       Date:  2006-12-22       Impact factor: 15.828

Review 3.  PTEN enters the nuclear age.

Authors:  Suzanne J Baker
Journal:  Cell       Date:  2007-01-12       Impact factor: 41.582

4.  Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma.

Authors:  M S Benassi; L Molendini; G Gamberi; G Magagnoli; P Ragazzini; G A Gobbi; L Sangiorgi; L Pazzaglia; J Asp; C Brantsing; P Picci
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

5.  Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines.

Authors:  R A Levine; M A Fleischli
Journal:  Vet Pathol       Date:  2000-01       Impact factor: 2.221

6.  Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export.

Authors:  Wan Jiao; Jashodeep Datta; Huei-Min Lin; Miroslav Dundr; Sushil G Rane
Journal:  J Biol Chem       Date:  2006-10-16       Impact factor: 5.157

7.  Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells.

Authors:  Monika Tataria; Natalina Quarto; Michael T Longaker; Karl G Sylvester
Journal:  J Pediatr Surg       Date:  2006-04       Impact factor: 2.545

8.  TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.

Authors:  Jay S Wunder; Nalan Gokgoz; Robert Parkes; Shelley B Bull; Sasha Eskandarian; Aileen M Davis; Chris P Beauchamp; Ernest U Conrad; Robert J Grimer; John H Healey; David Malkin; D C Mangham; Michael J Rock; Robert S Bell; Irene L Andrulis
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

9.  Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors.

Authors:  R A Levine; T Forest; C Smith
Journal:  Vet Pathol       Date:  2002-05       Impact factor: 2.221

10.  Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.

Authors:  A Koenig; S R Bianco; S Fosmire; J Wojcieszyn; J F Modiano
Journal:  Vet Pathol       Date:  2002-07       Impact factor: 2.221

View more
  4 in total

1.  Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Tomohiko Ito; Naohiro Oka; Ryosuke Kakinoki; Masao Akagi
Journal:  Eur J Histochem       Date:  2022-06-23       Impact factor: 1.966

2.  Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma.

Authors:  Branden A Smeester; Garrett M Draper; Nicholas J Slipek; Alex T Larsson; Natalie Stratton; Emily J Pomeroy; Kelsie L Becklin; Kenta Yamamoto; Kyle B Williams; Kanut Laoharawee; Joseph J Peterson; Juan E Abrahante; Susan K Rathe; Lauren J Mills; Margaret R Crosby; Wendy A Hudson; Eric P Rahrmann; David A Largaespada; Branden S Moriarity
Journal:  Mol Cancer Ther       Date:  2020-09-30       Impact factor: 6.261

3.  An Immunohistochemical Study of the PTEN/AKT Pathway Involvement in Canine and Feline Mammary Tumors.

Authors:  Pietro Asproni; Francesca Millanta; Lorenzo Ressel; Fabio Podestà; Francesca Parisi; Iacopo Vannozzi; Alessandro Poli
Journal:  Animals (Basel)       Date:  2021-02-01       Impact factor: 2.752

Review 4.  DNA damage response proteins in canine cancer as potential research targets in comparative oncology.

Authors:  Beatriz Hernández-Suárez; David A Gillespie; Aleksandra Pawlak
Journal:  Vet Comp Oncol       Date:  2022-01-10       Impact factor: 2.385

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.